Uncategorized
Rare disease biotech investment grows but UK lags

Investment in rare disease biotechs has increased following renewal of the FDA’s Priority Review Voucher (PRV) programme, according to SynaptixBio, but the United States remains dominant compared to the UK.
In February 2026, the PRV programme was signed into law and will remain in place until reviewed again in September 2029.
According to VC firm V-Bio, “reauthorisation of the FDA’s Rare Paediatric Disease PRV scheme has restored financial certainty and sparked intense interest from large pharma”.
PRVs are a prime source of non-dilutive capital. When a PRV is sold, the cash generated does not require the seller to issue new equity.
Dan Williams, CEO of SynaptixBio, said: “The US dominates because the PRV programme creates a highly valuable and, more importantly, tradable asset. VCs and private equity firms are far more willing to invest in rare disease biotechs simply because they provide a financial return on investment.”
PRVs have been sold recently for between $150 million to $200 million.
Williams added: “While the UK is known for high-quality science and innovation, it has seen a sharp contraction in biotech fundraising. Without an equivalent to the FDA PRV programme, UK rare disease biotechs rely heavily on public markets, private investment, or acquisition by larger global pharma to secure capital.”
The UK’s Achilles’ heel
According to market analysis by Schroder’s, from April 2026: “With public markets grappling with valuation volatility, the UK’s “golden triangle” of innovation – spanning London, Oxford, and Cambridge – continues to produce the next generation of biotech champions.
“Historically, the UK’s Achilles’ heel has been the “Valley of Death” – the gap between brilliant seed-stage science and the massive capital required for clinical trials. Too often, UK companies were forced to list in New York just to access the depth of capital needed to scale.”
In an article in Cure, Sergey Jakimov, Founding Partner at biotech VC firm LongeVC, said: “Orphan therapies are already projected to be roughly a fifth of global prescription revenue. Pharma needs de-risked, clinically validated assets, and rare disease programmes tend to show up better in diligence – clearer endpoints, smaller trials, engaged patient communities, and a higher likelihood of approval from Phase I.”
Jakimov continued: “You usually know the gene, you know the protein, and you know the patient. When a modality finally catches up to the biology, such as AAV gene therapy, ASOs, siRNA, base and prime editing – you can move from target ID to a clinical hypothesis in a shorter time span.”
Historically, it has been the US that has set the pace in rare disease drug design and development, creating incentives that make it very attractive for smaller biotechs who typically focus on addressing a single disease.
The Orphan Drug Act of 1980 set out a range of incentives that includes market exclusivity, tax credits, and support with getting into the clinic.
In the UK, the Medicines & Healthcare Regulatory Agency (MHRA) is consulting on a new regulatory framework for bringing rare disease drugs more quickly to market.
Williams concluded: “It would be ideal if the UK could introduce a scheme similar to the PRV. With the proposed new framework we have everything in place to better manage the clinical trial and marketing authorisation process for rare disease therapies, but it stops there.
“Reducing regulatory and approvals timescales and costs can only be good for rare disease patients and their families, but adding this stronger incentive could transform the industry, making the UK a leading player in research and development in this key area.
“We still aim to conduct clinical trials in the UK, using the results to inform further trials in the US, but this all depends on raising further investment.”
SynaptixBio is advancing an ASO that silences mutated genes without altering DNA, a targeted approach suited to the roughly 80% of rare diseases caused by single-gene mutations, against a backdrop where around one in 17 people will develop a rare disease but only 5% of the c10,000 known conditions have an approved treatment.
The post Rare disease biotech investment grows but UK lags appeared first on Drug Discovery World (DDW).
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read